Matthias A. Fante - Publications

De novo and quiescent cGVHD are distinguishable in a prognostic biomarker panel.

Journal: Frontiers in immunology

Published: December 03, 2025

Proposal for Diagnostic Criteria for Manifestations of Chronic Graft-versus-Host Disease in Peripheral Nervous System and Muscles.

Journal: Transplantation and cellular therapy

Published: November 10, 2025

Proposal for Diagnostic Criteria for Manifestations of Chronic Graft-versus-Host Disease in the Central Nervous System.

Journal: Transplantation and cellular therapy

Published: October 06, 2025

Sustained allogeneic kidney graft operational tolerance despite discontinued conventional immunosuppression after CD19-CAR-T cell therapy for relapsed/refractory posttransplant lymphoproliferative disorder.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: July 14, 2025

Microbiota-derived metabolites: Key modulators of cancer immunotherapies.

Journal: Med (New York, N.Y.)

Published: March 12, 2025

Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.

Journal: Transplantation and cellular therapy

Published: December 08, 2024

Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD.

Journal: Blood

Published: October 15, 2024

Metabolization of microbial postbiotic pentanoate drives anti-cancer CAR T cells.

Journal: bioRxiv : the preprint server for biology

Published: September 24, 2024

Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis.

Journal: Bone marrow transplantation

Published: September 04, 2024

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study).

Journal: Blood

Published: March 12, 2024

Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis.

Journal: Annals of hematology

Published: December 14, 2023

Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis.

Journal: Annals of hematology

Published: November 29, 2023